PeerView Oncology

 

PeerView Oncology
Avatar

45 y/o With EGFR+ NSCLC and Brain Mets: Should We Consider Mono or Combination Therapy & What Is the Next Step in Case of Liver Mets?

By PeerView Oncology FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
By PeerView Oncology FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
0 views
May 28, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

02:58
Lilly Medical Affairs

A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Lung
17:03
PeerView Oncology

Challenging Case of a 63 y/o Never-Smoking Female With TTF-1+ Lung A…

Feat. E. Garon, J. Heymach
15:20
PeerView Oncology

Locally Advanced and Early NSCLC IO Update: Will IO Change the Multi…

Feat. B. Stiles
15:18
PeerView Oncology

Managing EGFR+ NSCLC With CNS Metastases: Is There a Difference in C…

Feat. S. Patel
02:22
PeerView Oncology

45 y/o With EGFR+ NSCLC and Brain Mets: Should We Consider Mono or C…

Feat. S. Patel, M. Ahluwalia, K. Beal
05:24
PeerView Oncology

64 y/o Female With Newly Diagnosed Stage 4 NSCLC, EGFR exon 19 Mutat…

Feat. S. Patel, M. Ahluwalia, K. Beal
17:21
PeerView Oncology

Management of EGFR-Mutant Lung Cancer With Central Nervous System Me…

Feat. S. Patel, M. Ahluwalia, K. Beal
04:37
PeerView Oncology

41 y/o Female With Newly Diagnosed EGFR+ Stage 4 NSCLC and Brain Met…

Feat. S. Patel, M. Ahluwalia, K. Beal